Digital The cliff was never the crisis: Pharma’s strategy problem The patent cliff isn't the problem. It's the symptom.
Market Access Life sciences real estate is booming amid looming ‘patent cl... The life sciences sector across Europe has remained remarkably resilient in recent years, with record levels of growth and investment.
News Hengrui gets world-first okay for platelet drug hetrombopag Hengrui's oral TPO agonist, hetrombopag, is the first in the class to be approved for thrombocytopenia caused by chemotherapy for solid tumours.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
